Injectable ketorolac tromethamine recalled nationwide for potential cross-contamination
Nephron Pharmaceuticals is recalling Ketorolac Tromethamine Injection due to manufacturing deviations that could lead to cross-contamination. The recall affects 5,040 vials distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for an injectable pharmaceutical with potential cross-contamination resulting from manufacturing deviations. While no illnesses or injuries have been reported, injectable products with manufacturing defects present a risk of harm.
Plain-English summary
Ketorolac Tromethamine Injection, USP (60 mg/2 mL) manufactured by Nephron Pharmaceuticals Corporation is being recalled. The affected product is packaged in 2 mL single-dose vials with lot number 023011 (expiration date August 31, 2022).
The recall is due to cGMP deviations that could lead to potential cross-contamination. The FDA has classified this as a Class II recall.
The recall affects 5,040 vials distributed nationwide.
The recalled product
- Product
- KETOROLAC TROMETHAMINE (KETOROLAC TROMETHAMINE)
- Brand
- KETOROLAC TROMETHAMINE
- Manufacturer
- Nephron Sc Inc
- Category
- Drug — Injectable
- Hazard
- cross-contamination
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot#: 023011 Exp 8/31/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · KETOROLAC TROMETHAMINE
- HighKetorolac Tromethamine Injectable Recalled for Glass Particulate Matter
FDA (Drugs) · 2025-10-29
- HighKetorolac Ophthalmic Solution Recalled for Sterility Concerns Due to Improper Bottle Sealing
FDA (Drugs) · 2025-10-08
- HighKetorolac Tromethamine Ophthalmic Solution Recalled for Sterility Assurance Issues
FDA (Drugs) · 2025-07-02
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27